BioXcel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Allowance of U.S. Patent Application for Igalmi Dosing Regimen in Treating Acute Agitation
On July 15, 2025, BioXcel Therapeutics, Inc. announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 18/600,419. This patent, once issued, will cover the administration of a single dose of up to 120 mcg of dexmedetomidine in an oromucosal formulation for treating acute agitation associated with schizophrenia or bipolar disorder in certain patient subpopulations. This development aligns with the recommended IGALMI dosing regime and marks the 14th Orange Book listed patent for Igalmi. The patent is set to expire on January 12, 2043, subject to patent term adjustment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-067951), on July 15, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。